Xellia Pharmaceuticals, which specialises in producing medication to treat serious and life-threatening infections, has expanded its Budapest plant with a new building; the 13 million dollar investment will create 80 new, highly qualified workplaces at the facility in Köbánya, Kormány.hu reported.
Minister of Foreign Affairs and Trade Péter Szijjarto and CEO of Xellia Pharmaceuticals Carl-Ake Carlsson officially inaugurated on Monday the 3000 square metre building, which will house the company group’s global laboratory services centre.
Szijjarto said it was an economic policy priority for as many high added value workplaces based on research and development to be created in Hungary. “One of the most important ‘’flagships’ o this new economic policy goal is precisely the Hungarian pharmaceutical industry, in view of the fact that the pharmaceutical industry requires continuous research and development, and produced high added value products”, he stressed.
“Previous Hungarian economic policy could be summed up with the phrase ‘Made in Hungary’, but the situation has now changed; Made in Hungary is being replaced by Invented in Hungary, meaning that in future businesses should develop as many products and technologies as possible in Hungary. From this perspective, the pharmaceutical industry plays a leading role in Hungary”, the Minister explained.
